中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer

文献类型：期刊论文

作者Wang, Yonghui1,2,3; Chen, Binfan1,2; He, Zhidi1,2,4; Tu, Bin1,2,3; Zhao, Pengfei1; Wang, Huiyuan1; Asrorov, Akmal1,5; Muhitdinov, Bahtiyor1,5; Jiang, Jizong1,6; Huang, Yongzhuo1,2,3,7
刊名NANOSCALE
出版日期2022-02-10
卷号14期号:6页码:2304-2315
ISSN号2040-3364
DOI10.1039/d1nr06518a
通讯作者Huang, Yongzhuo(yzhuang@simm.ac.cn)
英文摘要Lung cancer is the top cause of cancer mortality in the world. Distant metastasis leads to high mortality. Abdominal metastasis of lung cancer is characterized by very poor prognosis and the median survival time is usually less than two months. Therefore, it is of clinical significance to develop a new effective method for the treatment of abdominal metastasis of lung cancer. Cell therapy has promoted the development of new technology and strategy in oncology. Macrophages, as an important component of solid tumors, have also attracted great attention as a promising strategy of cell therapy in oncology. However, the reinfusion of autologous macrophages would be easily "re-educated" by the tumor microenvironment into a phenotype that promotes tumor development. This work developed a potential therapy using celastrol nanoparticle-containing M1-like macrophages (NP@M1) as a combinatory therapeutic system. M1-like macrophages (M1 phi) not only can serve as a drug delivery carrier for celastrol but also as a biotherapeutic agent. In turn, the celastrol nanoparticles (NPs) can maintain an anticancer polarized status of M1 phi, and subsequently, the exocytosed NPs can also execute the tumor cell-killing effect. Such a system thus provides a "two-birds-one-stone" therapeutic strategy and a proof of concept for the currently incurable abdominal metastasis of lung cancer.
WOS关键词TUMOR ; OVERCOME ; CELLS
资助项目National Key Research and Development Program of China (China)[2021YFE0103100] ; National Key Research and Development Program of China (China)[2021YFC2400600] ; NFSC[81925035] ; NFSC[8201101172] ; NFSC[81803736] ; NFSC[81521005] ; Shanghai SciTech Innovation Initiative[19431903100] ; Shanghai SciTech Innovation Initiative[18430740800] ; Shanghai Collaborative Innovation Group of Early Diagnosis and Precise Treatment of Hemangiomas and Vascular Malformations[SSMU-ZDCX20180701]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
WOS记录号WOS:000747360500001
出版者ROYAL SOC CHEMISTRY
源URL[http://119.78.100.183/handle/2S10ELR8/300522]  
专题新药研究国家重点实验室
通讯作者Huang, Yongzhuo
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Chinese Acad Sci, Zhongshan Inst Drug Discovery, SIMM, Zhongshan 528437, Peoples R China
4.Kunming Med Univ, Dept Canc Biotherapy Ctr, Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China
5.Acad Sci Uzbek, Inst Bioorgan Chem, Tashkent, Uzbekistan
6.Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China
7.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Yonghui,Chen, Binfan,He, Zhidi,et al. Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer[J]. NANOSCALE,2022,14(6):2304-2315.
APA Wang, Yonghui.,Chen, Binfan.,He, Zhidi.,Tu, Bin.,Zhao, Pengfei.,...&Huang, Yongzhuo.(2022).Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer.NANOSCALE,14(6),2304-2315.
MLA Wang, Yonghui,et al."Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer".NANOSCALE 14.6(2022):2304-2315.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。